Stockscreener 앱 받기
1.40%
시간 외 거래:
Altimmune Inc 주식(ALT)의 최신 뉴스
Altimmune, Inc. (NASDAQ:ALT) Q1 2025 Earnings Call Transcript - Insider Monkey
Altimmune Reports Better-Than-Feared Q1 Loss, Secures $100M Credit Facility: Retail’s Pleased - MSN
Piper Sandler maintains Altimmune stock with $25 target - Investing.com Australia
Piper Sandler maintains Altimmune stock with $25 target By Investing.com - Investing.com Nigeria
Altimmune to Participate at Two Upcoming Investor Conferences | - GuruFocus
Altimmune Sets Double Conference Appearance: HC Wainwright and Jefferies Healthcare Events Coming Up - Stock Titan
Altimmune Inc (ALT) Q1 2025 Earnings Call Highlights: Financial Strength and Strategic Developments - Yahoo Finance
Altimmune’s 2025 Q1 Results Highlight Clinical Progress - TipRanks
Earnings call transcript: Altimmune Q1 2025 results show narrower loss By Investing.com - Investing.com Canada
Altimmune, Inc. SEC 10-Q Report - TradingView
Altimmune (ALT) Advances NASH Treatment and Secures $100M Credit Facility - GuruFocus
Altimmune outlines phase 3 pemvidutide plans and expands to alcohol-related liver indications while extending cash runway - MSN
Altimmune, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:ALT) - Seeking Alpha
ALTI Reports Strong Q1 Revenue Growth | ALTI Stock News - GuruFocus
Axsome’s $570M loan with Blackstone; Altimmune makes its own credit deal - Endpoints News
Earnings call transcript: Altimmune Q1 2025 results show narrower loss - Investing.com Australia
Altimmune (ALT) Sees Modest Pre-Market Rise After Earnings Repor - GuruFocus
Altimmune, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Altimmune (ALT) Secures $100 Million Credit Facility to Advance Pemvidutide Development | ALT Stock News - GuruFocus
Altimmune Secures Up To $100 Mln In Credit Facility From Hercules Capital - marketscreener.com
Altimmune (ALT) Q1 Revenue Steady as Pemvidutide Developments Pr - GuruFocus
Altimmune (ALT) Anticipates Q1 Earnings with Positive EPS Revisi - GuruFocus
Altimmune secures $100 million credit facility for drug development By Investing.com - Investing.com India
Altimmune Announces First Quarter 2025 Financial Results and Business Update - The Manila Times
Altimmune Secures Up to $100 Million in Credit Facility from Hercules Capital - The Manila Times
What to Expect from Altimmune's Earnings - Nasdaq
Stifel maintains Buy on Altimmune stock with $18 target By Investing.com - Investing.com UK
How Much Upside is Left in Altimmune (ALT)? Wall Street Analysts Think 285.86% - MSN
Shareholders that lost money on Altimmune, Inc.(ALT) should contact Levi & Korsinsky about pending Class ActionALT - ACCESS Newswire
FINAL ALT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Altimmune, Inc. Investors to Join the Class Action Lawsuit - ACCESS Newswire
Altimmune's (ALT) Pemvidutide Shows Promising Results in Liver H - GuruFocus
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ | ALT Stock News - GuruFocus
Altimmune Presents New Analyses Predicting High Rates of MASH Resolution on Biopsy following Pemvidutide Treatment at the EASL International Liver Congress™ - The Manila Times
Altimmune Presents Promising Analyses of Pemvidutide's Efficacy in MASH Treatment at EASL 2025 - Nasdaq
Altimmune at The Citizens JMP Life Sciences Conference: Pembidutide’s Promise - Investing.com
Altimmune to Report First Quarter 2025 Financial Results and Pro - GuruFocus
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 | ALT Stock News - GuruFocus
Altimmune to Report First Quarter 2025 Financial Results and Provide Business Update on May 13, 2025 - The Manila Times
Altimmune, Inc. to Announce Q1 2025 Financial Results on May 13, 2025 - Nasdaq
Clinical-Stage Biotech Altimmune Sets Q1 2025 Earnings Date: Key Financial Updates Coming May 13 - Stock Titan
Trend Tracker for (ALT) - news.stocktradersdaily.com
Lost Money on Altimmune, Inc.(ALT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
What's Going On With Altimmune (ALT) Stock Today? - Benzinga
Press Release Distribution & PR Platform - ACCESS Newswire
Altimmune to Present at Upcoming EASL International Liver Congress™ 2025 - The Manila Times
Altimmune, Inc. to Showcase Novel MASH Resolution Index Data for Pemvidutide at EASL International Liver Congress™ 2025 - Nasdaq
Altimmune to Participate in the Citizens Life Sciences Conferenc - GuruFocus
Altimmune to Participate in the Citizens Life Sciences Conference - The Manila Times
Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance
2.45%
자본화:
|
볼륨(24시간):